Samtheo Biopharma Forms Subsidiary Lyndor Bioscience to Develop Moffitt Cancer Center Rx | GenomeWeb

Samtheo Biopharma, a company formed last year to acquire and develop technology related to targeted therapeutics and personalized medicine, has licensed from Florida's H. Lee Moffitt Cancer Center a small molecule with the potential to treat cancer patients with chemotherapeutic and radiation resistance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.